Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma invitro and invivo

Cytotherapy

Volumn 17, Issue 5, 2015, Pages 601-612

  Pérez Martínez, Antonio ^a   Valentín, Jaime ^a   Fernández, Lucía ^b   Hernández Jiménez, Enrique ^a   López Collazo, Eduardo ^a   Zerbes, Petra ^c   Schwörer, Ellen ^c   Nuñéz, Fernando ^d   Martín, Inmaculada Génesis ^d   Sallis, Hannah ^e   Díaz, Miguel Ángel ^f   Handgretinger, Rupert ^c   Pfeiffer, Matthias Manuel ^c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Clinical Research Program   (Spain)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Arabinoxylan rice bran (MGN 3 Biobran); Cytotoxic activity; Natural killer (NK) cells; Neuroblastoma

Indexed keywords

ARABINOXYLAN; CD69 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR 4; T LYMPHOCYTE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; POLYSACCHARIDE MGN3; XYLAN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL ACTIVATION; CELL EXPANSION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JURKAT CELL LINE; K562 CELL LINE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RICE BRAN; T LYMPHOCYTE; UPREGULATION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; FLUORESCENCE; IMMUNOLOGY; IMMUNOPHENOTYPING; KINETICS; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; ORYZA; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FLUORESCENCE; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; KINETICS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MICE, INBRED NOD; MICE, SCID; NEUROBLASTOMA; ORYZA; RECEPTORS, NATURAL KILLER CELL; XYLANS;

EID: 84933677594     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.11.001     Document Type: Article

References (44)

1. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000, 356:1795-1799.
2. Lang P., Pfeiffer M., Teltschik H.M., Schlegel P., Feuchtinger T., Ebinger M., et al. Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. Best Pract Res Clin Haematol 2011, 24:403-411.
3. Nakachi K., Imai K. Environmental and physiological influences on human natural killer cell activity in relation to good health practices. Jpn J Cancer Res 1992, 83:798-805.
4. Kusaka Y., Kondou H., Morimoto K. Healthy lifestyles are associated with higher natural killer cell activity. Prev Med 1992, 21:602-615.
5. Li Q., Morimoto K., Nakadai A., Qu T., Matsushima H., Katsumata M., et al. Healthy lifestyles are associated with higher levels of perforin, granulysin and granzymes A/B-expressing cells in peripheral blood lymphocytes. Prev Med 2007, 44:117-123.
6. Reale M., Boscolo P., Bellante V., Tarantelli C., Di Nicola M., Forcella L., et al. Daily intake of Lactobacillus casei Shirota increases natural killer cell activity in smokers. Br J Nutr 2012, 108:308-314.
7. Hirose Y., Murosaki S., Yamamoto Y., Yoshikai Y., Tsuru T. Daily intake of heat-killed Lactobacillus plantarum L-137 augments acquired immunity in healthy adults. JNutr 2006, 136:3069-3073.
8. Crist D.M., Kraner J.C. Supplemental growth hormone increases the tumor cytotoxic activity of natural killer cells in healthy adults with normal growth hormone secretion. Metabolism 1990, 39:1320-1324.
9. Henney C.S., Kuribayashi K., Kern D.E., Gillis S. Interleukin-2 augments natural killer cell activity. Nature 1981, 291:335-338.
10. Kobayashi H., Dubois S., Sato N., Sabzevari H., Sakai Y., Waldmann T.A., et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005, 105:721-727.
11. Kalina U., Kauschat D., Koyama N., Nuernberger H., Ballas K., Koschmieder S., et al. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. JImmunol 2008, 165:1307-1313.
12. Watanabe M., Fenton R.G., Wigginton J.M., McCormick K.L., Volker K.M., Fogler W.E., et al. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response invivo that is independent of endogenous IL-12 production. JImmunol 1999, 163:1943-1950.
13. Szkaradkiewicz A., Karpiński T.M., Drews M., Borejsza-Wysocki M., Majewski P., Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. JBiomed Biotechnol 2010, 2010:901564.
14. Konjević G., Mirjacić Martinović K., Vuletić A., Jović V., Jurisić V., Babović N., et al. Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007, 24:1-11.
15. Choi B.S., Sondel P.M., Hank J.A., Schalch H., Gan J., King D.M., et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother 2006, 55:761-774.
16. Pahl J.H., Ruslan S.E., Buddingh E.P., Santos S.J., Szuhai K., Serra M., et al. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. Clin Cancer Res 2012, 18:432-441.
17. Lundqvist A., Yokoyama H., Smith A., Berg M., Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009, 113:6120-6127.
18. Ghoneum M., Abedi S. Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN-3/Biobran). JPharm Pharmacol 2004, 56:1581-1588.
19. Ghoneum M. Enhancement of human natural killer cell activity by modified arabinoxylane from rice bran (MGN-3). Int J Immunother 1998, 14:89-99.
20. Ghoneum M., Gollapudi S. Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 invitro. Neoplasma 2011, 58:118-123.
21. Bang M.H., Van Riep T., Thinh N.T., Song le H., Dung T.T., Van Truong L., et al. Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial. Anticancer Res 2010, 30:5145-5151.
22. Gollapudi S., Ghoneum M. MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin. Cancer Detect Prev 2008, 32:1-6.
23. Ghoneum M., Gollapudi S. Modified arabinoxylan rice bran (MGN-3/Biobran) sensitizes human T cell leukemia cells to death receptor (CD95)-induced apoptosis. Cancer Lett 2003, 201:41-49.
24. Ghoneum M., Gollapudi S. Synergistic role of arabinoxylan rice bran (MGN-3/Biobran) in S.cerevisiae-induced apoptosis of monolayer breast cancer MCF-7 cells. Anticancer Res 2005, 25:4187-4196.
25. Markus J., Miller A., Smith M., Orengo I. Metastatic hemangiopericytoma of the skin treated with wide local excision and MGN-3. Dermatol Surg 2006, 32:145-147.
26. Sims T.L., Williams R.F., Ng C.Y., Rosati S.F., Spence Y., Davidoff A.M. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 2008, 144:269-275.
27. Perez-Martinez A., Iyengar R., Gan K., Chotsampancharoen T., Rooney B., Holladay M., et al. Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:598-607.
28. Cho D., Shook D.R., Shimasaki N., Chang Y.H., Fujisaki H., Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010, 16:3901-3909.
29. Blomberg K., Granberg C., Hemmilä I., Lövgren T. Europium-labelled target cells in an assay of natural killer cell activity. II. A novel non-radioactive method based on time-resolved fluorescence. significance and specificity of the method. JImmunol Methods 1986, 92:117-123.
30. Badr El-Din N.K., Noaman E., Ghoneum M. Invivo tumor inhibitory effects of nutritional rice bran supplement MGN-3/Biobran on Ehrlich carcinoma-bearing mice. Nutrition Cancer 2008, 60:235-244.
31. Takahara K., Sano K. The life prolongation and QOL improvement effect of rice bran arabinoxylan derivative (MGN-3, BioBran) for progressive cancer. Clin Pharmacol Therapy 2004, 14:267-271.
32. Cholujova D., Jakubikova J., Czako B., Martisova M., Hunakova L., Duraj J., et al. MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. Cancer Immunol Immunother 2013, 62:437-445.
33. Meurs E.F., Galabru J., Barber G.N., Katze M.G., Hovanessian A.G. Tumor suppressor function of the interferon-induced double-stranded RNA activated protein kinase. Proc Natl Acad Sci U S A 1993, 90:232-236.
34. Ghoneum M.1, Badr El-Din N.K., Ali D.A., El-Dein M.A. Modified arabinoxylan from rice bran, MGN-3/biobran, sensitizes metastatic breast cancer cells to paclitaxel invitro. Anticancer Res 2014, 34:81-87.
35. Dons'koi B.V., Chernyshov V.P., Osypchuk D.V. Measurement of NK activity in whole blood by the CD69 up-regulation after co-incubation with K562, comparison with NK cytotoxicity assays and CD107a degranulation assay. JImmunol Methods 2011, 372:187-195.
36. Benlahrech A., Donaghy H., Rozis G., Goodier M., Klavinskis L., Gotch F., et al. NK Cell up-regulation of CD69, HLA-DR, interferon γ secretion and cytotoxic activity by plasmacytoid dendritic cells is regulated through overlapping but different pathways. Sensors (Basel) 2009, 9:386-403.
37. Borrego F., Robertson M.J., Ritz J., Pena J., Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999, 97:159-165.
38. Clausen J.1, Vergeiner B., Enk M., Petzer A.L., Gastl G., Gunsilius E. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology 2003, 207:85-93.
39. Ghoneum M., Matsuura M. Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran). Int J Immunopathol Pharmacol 2004, 17:283-292.
40. Ghoneum M., Matsuura M., Gollapudi S. Modified arabinoxylan rice bran (MGN-3/Biobran) enhances intracellular killing of microbes by human phagocytic cells invitro. Int J Immunopathol Pharmacol 2008, 21:87-95.
41. Alici E., Sutlu T., Bjorkstrand B., Gilljam M., Stellan B., Nahi H., et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008, 111:3155-3162.
42. Voskens C.J., Watanabe R., Rollins S., Campana D., Hasumi K., Mann D.L. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. JExp Clin Cancer Res 2010, 29:134-146.
43. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
44. Ghoneum M., Jewett A. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 invitro. Cancer Detect Prev 2000, 24:314-324.